Start free
Workflows

Indication selection

Choose the lead indication for your platform: Sleuth tests each disease it could treat for proof your mechanism helps, maps who’s already there, and sizes the patients.

Run Indication selection
Same workflow, two names

In Studio's workflow library, Indication selection is called Novel Platform to Positioning. It's the same workflow as the Indication Selection page on sleuthinsights.com.

Use it when

  • Your platform could treat many diseases and you can fund one program first.
  • You need a defensible lead before a raise, a board meeting, or a partnering push.
  • You're the CEO, CSO, or first BD hire at a platform biotech, or you're weighing a lead asset's next indication.

What to have ready

How your platform works, what sets it apart, the decision you face, and any diseases you're already weighing. Add your deck if you have one. You can start from a single lead asset instead of a platform: describe it the same way.

How it runs

  1. Describe your platform. The mechanism, what it does better, and the areas you'd consider.
  2. Decide what counts. Choose what matters most, such as clinical validation, unmet need, competitive room, and fit with your platform, and how much each one counts.
  3. Shape the plan. Sleuth shows its three steps: test every candidate disease, map the competition, and size each position. Add a disease or drop one before it runs.
  4. Get the analysis. A recommendation on where to lead, with the evidence behind every disease, and the datasets to keep working in.

What you get

Your questionWhat Sleuth gives you
Does our mechanism work in this disease?Every disease your platform could treat, tested for human proof that your mechanism helps and for a fit with how you'd dose it. A failed trial counts against a disease, and Sleuth records why it ruled out each one.
Who's already there, and how close are they to us?Every program in each shortlisted disease, from preclinical to approved, sorted by how close its mechanism comes to yours.
How many patients, and what are they worth?The patients each position would serve in your markets, and what they're worth at branded prices against what's spent on them today.
Where should we lead, and what must the first trial show?A recommendation on the lead, the second, and the ones to drop, with what your first trial has to show in each.

A finished example

Where should an antibody-removal platform lead? Sleuth says AQP4-positive NMOSD. Sleuth tested 9 candidate diseases, shortlisted 3, and found that none of NMOSD's 94 programs removes the antibody that causes it. See the full example

Questions

What if we already have diseases in mind?

Add them in step 1. Sleuth tests them alongside every other candidate, so you can see how your list compares.

Why was a disease ruled out?

Sleuth lists the test each one missed and the reason, such as no single antibody that causes the disease, or a removal trial that missed its endpoint.

How many diseases does it look at?

Every disease your platform could treat in the areas you name, not only the ones on your list. In the example, Sleuth tested 9 candidates and shortlisted 3.

Does it size the market?

Yes. For each shortlisted disease, Sleuth sizes the patients in your markets and what they'd be worth at branded prices, next to what's spent on them today.

Can I change the weights after it runs?

Yes. Change a weight, and Sleuth ranks the diseases again.

Credits

The plan shows the size of the job before anything runs: rows times analytical columns is the credits it will use. How credits work

Next questions on the same project

Graveyard analysis checks whether your lead repeats an old failure. Standard of care evolution picks the patients for the first pivotal trial. Pharma partnering lines up who to pitch.